Healthcare

Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer

ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentially Positive signal in progression-free survival…

6 months ago

Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards

Recognition highlights EluPro™ Antibiotic-Eluting BioEnvelope’s impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators SILVER SPRING, Md.,…

6 months ago

Liviniti Achieves HITRUST i1 Certification for Industry-Leading Security Practices

Certification demonstrates Liviniti's strong commitment to data security and risk managementNatchitoches, Louisiana--(Newsfile Corp. - June 26, 2025) - Liviniti, a…

6 months ago

Hemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible Debenture

Calgary, Alberta--(Newsfile Corp. - June 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")…

6 months ago

Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with…

6 months ago

ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation…

6 months ago

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated…

6 months ago

Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with…

6 months ago

Tilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD Formulations

New Study Provides Insight into the Bioavailability of Medical Cannabis Formulations for Therapeutic TreatmentNEW YORK, June 26, 2025 (GLOBE NEWSWIRE)…

6 months ago